Navigation and service

In Search of New Painkillers

Jülich neuroscientists are partners in a research project aiming to support the development of new painkillers



Jülich/Aachen, 16 November 2017 – Drug development entails huge challenges, particularly when the aim is to find solutions for patients whose pain cannot be adequately treated with current medications. Complex disease mechanisms must be clarified and improved drugs developed. Neuroscientists from Forschungszentrum Jülich are involved in the project entitled “Development of PET-ligands to demonstrate the duality of the mechanisms of action of new analgesics” (Dual2PET), which aims to support the development of new drugs with dual mechanisms of action for chronic pain which is currently difficult to treat. The State of North Rhine-Westphalia selected the project for funding within the LifeSciences.NRW lead market competition. Dual2PET will receive € 2 million over three years from the European Regional Development Fund and the State of North Rhine-Westphalia.

read more (in German)

Logo

 

 

 

YOUR OPINION MATTERS!

 

Dear visitor,

To make our website suit your needs even more and to give it a more appealing design, we would like you to answer a few short questions.

Answering these questions will take approx. 10 min.

Start now Close window

Thank you for your support!

 

In case you have already taken part in our survey or in case you have no time to take part now, you can simply close the window by clicking "close".

If you have any questions on the survey, please do not hesitate to contact: webumfrage@fz-juelich.de.

 

Your Team at Forschungszentrum Jülich

 

Note: Forschungszentrum Jülich works with the market research institute SKOPOS to anonymously conduct and analyze the survey. SKOPOS complies with the statutory requirements on data protection as well as with the regulations of ADM (Arbeitskreis Deutscher Markt- und Sozialforschungsinstitute e.V.) and ESOMAR (Europäische Gesellschaft für Meinungs- und Marketingforschung). Your data will not be forwarded to third parties.